NEW YORK (GenomeWeb) – Trovagene said today that it has entered into an agreement with Chinese genomics service provider Novogene under which Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.

Trovagene is selling Novogene the NextCollect device along with reagents and methods to extract cell-free DNA (cfDNA) from urine. Novogene will then validate the platform at its own facilities, which include a CAP-accredited lab in Tianjin, China.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.